Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10

Methods Patients aged >=2 years who were treated with IVIG (IV-switchers) or SCIG (SC-switchers) immediately before study entry received Gammagard Liquid (IVIG10%) at the monthly dose equivalent to their recent prestudy treatment for 3 months. Results Infusion rates of >=60 mL/h/site for more than one infusion were reached by 58.8% (30/51) of IV-switchers and 65.2% (15/23) of SC-switchers; the median infusion number when patients first reached 60 mL/h/site was 3 for both groups.